



CALIFORNIA TECHNOLOGY ASSESSMENT FORUMSM

Insulin Degludec for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

Questions for Deliberation: February 12, 2016 Public Meeting

1. For patients with type 1 diabetes mellitus (DM), is the evidence adequate to demonstrate that the net health benefit of treatment with ***insulin degludec*** is greater than that of treatment with ***insulin glargine***?
Yes No
2. Given the available evidence for patients with type 1 DM, what is the care value* of treatment with ***insulin degludec*** vs. treatment with ***insulin glargine***?
a. Low b. Intermediate c. High
3. Given the available evidence for patients with type 1 DM, what is the provisional health system value** of treatment with ***insulin degludec*** vs. treatment with ***insulin glargine***?
a. Low b. Intermediate c. High
4. For patients with type 2 DM on basal-only insulin regimens, is the evidence adequate to demonstrate that the net health benefit of treatment with ***insulin degludec*** is greater than that of treatment with ***insulin glargine***?
Yes No
5. Given the available evidence for patients with type 2 DM who are on basal-only insulin regimens, what is the care value* of treatment with ***insulin degludec*** vs. treatment with ***insulin glargine***?
a. Low b. Intermediate c. High
6. Given the available evidence for patients with type 2 DM who are on basal-only insulin regimens, what is the provisional health system value** of treatment with ***insulin degludec*** vs. treatment with ***insulin glargine***?
a. Low b. Intermediate c. High
7. For patients with type 2 DM who are on basal-bolus insulin regimens, is the evidence adequate to demonstrate that the net health benefit of treatment with ***insulin degludec*** is greater than that of treatment with ***insulin glargine***?
Yes No
8. Given the available evidence for patients with type 2 DM who are on basal-bolus insulin regimens, what is the care value* of treatment with ***insulin degludec*** vs. treatment with ***insulin glargine***?
a. Low b. Intermediate c. High
9. Given the available evidence for patients with type 2 DM who are on basal-bolus insulin regimens, what is the provisional health system value** of treatment with ***insulin degludec*** vs. treatment with ***insulin glargine***?
a. Low b. Intermediate c. High

* **Care value** is determined by looking at four elements: comparative clinical effectiveness, incremental costs per outcomes achieved, other benefits or disadvantages, and contextual considerations. Care value represents the long-term perspective, at the individual patient level, on patient benefits and the incremental costs to achieve those benefits.

** **Provisional health system value** represents a judgment integrating consideration of the long-term care value of a new intervention with an analysis of its potential short-term budget impact if utilization is unmanaged.